A high performance liquid chromatography method with tandem mass spectrometry detection is described for the determination of paroxetine, an antidepressant drug, and its metabolite (3S, 4R)-4-(4-fluorophenyl)-3-(4-hydroxy-3-methoxyphenoxymethyl) piperidine (HM paroxetine) in human plasma. Plasma samples were hydrolyzed with hydrochloric acid and then analytes were extracted with ethyl acetate at alkaline pH. Extracts were analysed by high performance liquid chromatography coupled to an atmospheric pressure ionisation-electrospray (ESI) interface and an ion trap mass spectrometer. Chromatography was performed on a reversed-phase column using acetonitrile/0.02% formic acid 
Introduction
Paroxetine, (3S, 4R)-(4-(4-fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine), is an antidepressant which acts as a potent selective serotonine re-uptake inhibitor (SSRI) in the central nervous system. 1 It has been successfully used worldwide for the treatment of a variety of depression, obsessive-compulsive and panic states and other psychiatric disorders. 2, 3 In humans, paroxetine is initially O-demethylenated by CYP2D6, an isoenzyme of cytochrome P450 giving rise to an unstable catechol ((3S, 4R)-4-(4-fluorophenyl)-3-(3,4-dihydroxyphenoxymethyl)piperidine) which is then methylated in the C3 or C4
positions of the benzene ring. A minor metabolic pathway of the catechol metabolite has also been described leading to the formation of the (3S, 4R)-4-(4-fluorophenyl)-3-(hydroxymethyl)piperidine metabolite. [3] [4] [5] [6] The methylation of catechol is putatively catalyzed by catechol-O-methyltransferase (COMT) and the predominant metabolite resulting from this O-methylation is (3S, 4R)-4-(4-fluorophenyl)-3-(4-hydroxy-3-methoxyphenoxymethyl)piperidine (HM paroxetine). This major metabolite was isolated from human urine and identified by mass spectrometry as conjugated to glucuronic acid and sulphate. 7 Paroxetine metabolites have been reported to be pharmacologically inactive in vitro and ex-vivo and they are not likely to contribute to the clinical effects of paroxetine. 1, 2, 5, 8 Metabolites have been described to appear in plasma simultaneously with paroxetine, suggesting a first-pass metabolism. 3, 6 Non-linear pharmacokinetics behaviour has been described for paroxetine. 5, 6, 9 Pharmacokinetic properties of paroxetine in healthy volunteers have been characterized following both single and multiple oral doses in several studies. 3, 5, 6, 10 However, although paroxetine metabolites have been described in preliminary reports and HM paroxetine has been always reported as a major metabolite 6, 7 , to our knowledge its pharmacokinetic properties in humans have never been reported in peer reviewed scientific journals. Moreover, the only attempt to detect HM paroxetine in plasma samples involved the determination of its free form; 10 in the event, HM paroxetine was only found in one patient over a series of seven after repeated doses. The drug was administered at 9.00 a.m. to the subjects in a fasting state. Blood samples were obtained through a catheter inserted into a peripheral vein before (0 h) and at 1, 3, 5, 8 and 24 h after drug administration. Blood was collected in heparinized tubes. Within 30 minutes after drawing, samples were centrifuged at 1100 g and 4ºC for 10 minutes, and plasma was stored at -20ºC until analysis. Urine was also collected at different time periods from all volunteers: 0-3 h, 3-6 h, 6-9h, 9-12h, 12-24 h.
Subjects were phenotyped for CYP2D6 activity using dextromethorphan as drug probe. The dextromethorphan/dextrorphan urinary metabolic ratio 12 was used to classify subjects as extensive or poor metabolizers. All participants were extensive metabolizers. -one aliquot of urine was extracted without applying any hydrolysis procedure;
-one aliquot of urine underwent an acidic hydrolysis as described for plasma samples;
-one aliquot of urine underwent an enzymatic hydrolysis with sulfatase (1 mg/mL) in one mL 0.1 M sodium acetate buffer, pH 5.2, 3h at 55ºC; -one aliquot of urine underwent an enzymatic hydrolysis with glucuronidase (30 µL β-glucuronidase in one mL 0.2M sodium phosphate buffer, pH 7.0) for 3h at 55ºC.
After incubation, samples were cooled at room temperature, adjusted to pH 12 with NaOH (10 M) and extracted as described for plasma samples. Extracted urine samples were analyzed by LC/MS/MS with the same conditions as those used for plasma samples. Aliquots of drug-free urine underwent the same hydrolysis treatments and were used to verify absence of chromatographic interferences. All the experiments were carried out in duplicate.
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Validation procedure. Prior to the application to real plasma samples, the method was tested following a 3-day validation protocol. Selectivity, recovery, linearity, stability, precision, accuracy, and limits of detection and quantification were assayed.
The selectivity of the method was studied by analysing several plasma samples Signal-to-noise ratios of 3 and 10 were used for estimating the limits of detection and quantification, respectively. The quantification limits were verified by the analysis of five samples prepared at the respective quantification limits estimated as described.
Analytical recoveries were calculated by comparing the peak areas obtained when calibration samples were analysed by adding the reference substances and the internal standards prior to and after the extraction procedure in the drug-free plasma and in the extract from drug-free plasma, respectively. The recoveries were assessed at three concentration levels using four replicates at each level (3, 25 and 100 µg/L) for paroxetine and (5, 25 and 100 µg/L) for HM paroxetine and twelve replicates for both I.S. at a concentration of 30 µg/L.
Three replicates of quality control samples at three different concentrations of paroxetine (4, 40 and 80 µg/L) and HM paroxetine (6, 40 and 80 µg/L) added to drug-free plasma samples were extracted as reported above and analysed for the determination of intra-assay precision and accuracy. The inter-assay precision and accuracy were determined for three independent experimental assays of the aforementioned replicates. Inter and intra-assay precision were expressed as the relative SD (RSD) of concentrations calculated for quality control samples. Inter and intra-assay accuracy were expressed as the mean of the absolute value of the relative error of the calculated concentrations.
The stability of paroxetine and its metabolite in plasma was evaluated under three freeze/thaw cycles. The test involved a comparison of replicate stability samples, which had been frozen and thawed three times with a fresh plasma sample that had been thawed only once.
(h), and AUC (0-24h) (µg/L.h) were determined using the PK Functions for Microsoft Excel computer program.
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RESULTS AND DISCUSSION
Validation results
The full scan MS/MS spectra as well as the proposed fragmentation patterns for paroxetine, HM paroxetine, methoxyphenamine and pholedrine, are shown in Figure 1 . paroxetine. In the case of analysis, in three samples out of nine at 1h after administration, the drug was detected but could not be quantified. On the other hand, samples which had a concentration higher than 100 µg/L of HM paroxetine were diluted with ultrapure water to fit within the working range, and were reanalysed using the same sample preparation procedure described above.
The freeze-thaw stability test showed that paroxetine and its metabolite (HM paroxetine) in human plasma were stable for at least three freeze-thaw cycles (data not shown). Moreover, the stability of HM paroxetine under the hydrolysis conditions was established when analytical recoveries were calculated by comparing the peak areas obtained when calibration samples were analysed by adding the reference substance and the internal standards both prior to and after the extraction procedure. HM paroxetine was stable under acidic hydrolysis conditions, as good responses were obtained from 11 calibration samples when HM paroxetine and the internal standard had been added prior to the extraction procedure.
Because deuterated analogues of paroxetine were not commercially available, it was necessary to find an alternative internal standard. Methoxyphenamine has proven to be a good choice because it shares several physicochemical properties with paroxetine, making it suitable for this type of analysis. Our previous experience with the analysis of drugs bearing a 4-hydroxy-3-methoxy grouping like HMMA (4-hydroxy-3-methoxymethamphetamine) 15 , using pholedrine as internal standard, showed good results and therefore it was selected for the analysis of HM paroxetine in the present study.
The analytical method presented here for the simultaneous determination of paroxetine and HM paroxetine from plasma samples has demonstrated enough sensitivity, specificity and selectivity for the purposes of the present study. Highperformance liquid chromatography (HPLC) with ultaviolet (UV), fluorescence or coulometric detection was utilized in previously published analytical methods. [16] [17] [18] [19] [20] [21] [22] [23] [24] However, these detectors were not sufficiently specific and sensitive for the determination of paroxetine, and required laborious and time-consuming sample pretreatment to remove interfering substances and/or the formation of derivates before HPLC analysis. Recently a LC/MS/MS method for paroxetine determination in plasma has been reported. 25 However, this method does not include the analysis of its main metabolite.
Despite the extensive number of assay procedures for the determination of paroxetine published up to now [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] , only two studies describe the simultaneous determination of paroxetine and its metabolite HM paroxetine in plasma. 10, 24 Kristoffersen et al. 24 provided detection limits around 0.025 µmol/L (8 µg/L) for paroxetine and 0.12 µmol/L (40 µg/L) for HM paroxetine, which are of use in cases of acute intoxication but are not suitable for the purposes of a pharmacokinetic study in which a single dose of 20 mg is administered and lower concentrations are expected for the parent drug and its metabolite. However, results obtained for real cases of acute paroxetine intoxications were not reported, and it is unknown if the method, as it was described 24 , is able to detect HM paroxetine in clinical samples. On the other hand,
Härtter et al. 10 described a method for paroxetine and its main metabolite for application in pharmacokinetic studies; HM paroxetine was detected in some samples but could not be quantified. Our previous experience with drugs bearing a methylene-dioxy grouping like MDMA (3,4-methylendioxymethamphetamine) 28 showed that the corresponding hydroxy-methoxy metabolite, HMMA (3-hydroxy-4-methoxy-methamphetamine), is extensively conjugated and that despite very sensitive assays this metabolite in its free form was not quantifiable. This observation oriented the method development towards the introduction of a hydrolysis step in the sample preparation procedure. The kinetics of HM paroxetine in plasma and urine samples has never been reported, but some studies from the pharmaceutical company that developed the drug suggest that this metabolite is mainly excreted as a conjugate. 6, 7 Application to pharmacokinetic study concentrations along the time course of the experimental session. The pharmacokinetic parameters calculated for paroxetine and HM paroxetine are reported in Table 3 .
Paroxetine was identified in both hydrolysed and non-hydrolysed urine samples.
In contrast, HM paroxetine could not be identified in non-hydrolysed samples, while it was always present in hydrolysed urine, independently from the hydrolysis procedure applied. This observation confirms early results that HM paroxetine is presented in biological fluids mainly as the sulfate and the glucuronoconjugate. 6, 7 Pharmacokinetic parameters obtained here for paroxetine are in agreement with previously published data. 2, 6, 29 Concerning HM paroxetine, this is the first time that this metabolite has been determined. The fact that the T max of HM paroxetine precedes marginally that corresponding to paroxetine (3 h vs. 5 h), combined with the high HM paroxetine plasma concentrations, support a strong first-pass metabolism and may explian the inter-subject variabilities observed among the 9 healthy volunteers participating in the study (Figure 4 ).
It is worth noting that, when Härtter et al. 10 analysed HM paroxetine without any hydrolysis step, this metabolite was hardly found in plasma samples of volunteers also administered 20 mg of paroxetine, and the reported limit of detection for HM paroxetine was 5 μg/L. If this figure is compared with the encountered concentrations of HM paroxetine (sum of its conjugated and unconjugated form) (C max 92.40 µg/L), it can be estimated that HM paroxetine is conjugated in plasma to an extent most probably higher than 95%. This hypothesis is confirmed from results observed in urine samples. Indeed
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HM paroxetine could not be found in non-hydrolysed urine, while it was observed after acidic and enzymatic hydrolysis with glucuronidase and sulfatase.
The simultaneous determination of paroxetine and HM paroxetine is expected to provide some insight into the non-linear kinetics reported for paroxetine after repeated doses. 5, 6, 9 During metabolism, the methylation of the unstable catechol metabolite (3S, The possibility of a co-analysis of both metabolites should be considered. However, many reports 5, 7, 10 suggest that methylation at the C3 position (HM paroxetine) is the predominant paroxetine pathway and, moreover, it is known that COMT prefentially alkylates compounds containing phenol moieties at the 3 position, and to a much lesser extent at position 4. 30 If a co-analysis method were available, it is highly likely that concentrations of the metabolite methylated at C4 would be much lower in comparison with that of HM paroxetine.
CONCLUSIONS
In conclusion, the LC/MS/MS method presented here for the simultaneous determination of paroxetine and HM paroxetine requires only a one-step extraction with ethyl acetate for plasma samples prior to isocratic chromatography, which enables a 
